PainReform SG&A Expenses 2020-2024 | PRFX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

PainReform sg&a expenses from 2020 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

PainReform sg&a expenses from 2020 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$69.6B
Zoetis (ZTS)	$69B
Takeda Pharmaceutical (TAK)	$48.7B
Daiichi Sankyo, - (DSNKY)	$47.9B
BeOne Medicines - (ONC)	$34.4B
Sandoz Group AG (SDZNY)	$26.7B
Summit Therapeutics (SMMT)	$19.3B
Merck (MKKGY)	$16.7B
Shionogi (SGIOY)	$14.9B
United Therapeutics (UTHR)	$14B
Neurocrine Biosciences (NBIX)	$13.4B
IPSEN (IPSEY)	$11.3B
Orion OYJ (ORINY)	$11.2B
Eisai (ESAIY)	$9.1B
Madrigal Pharmaceuticals (MDGL)	$9B
Corcept Therapeutics (CORT)	$7.5B
Grifols, S.A (GRFS)	$6.9B
Stevanato Group S.p.A (STVN)	$6.9B
Ionis Pharmaceuticals (IONS)	$6.9B
Ono Pharmaceutical (OPHLF)	$5.7B
Hikma Pharmaceuticals Plc (HKMPF)	$5.4B
Soleno Therapeutics (SLNO)	$3.7B
Procaps Group, S.A (PROCF)	$3.2B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$3B
Crinetics Pharmaceuticals (CRNX)	$2.8B
NewAmsterdam Pharma (NAMS)	$2.8B
Hypermarcas (HYPMY)	$2.7B
Catalyst Pharmaceuticals (CPRX)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.3B
Ocular Therapeutix (OCUL)	$2.1B